| Bioactivity | PCI-34051 is a potent and selective HDAC8 inhibitor with IC50 of 10 nM, with >200-fold selectivity over the other HDAC isoforms. | ||||||||||||
| Invitro | PCI-34051 inhibits pure recombinant HDAC8 with Ki of 10 nM with >200-fold selectivity over the other HDACs tested, including HDACs 1, 2, 3, 6 and 10. PCI-34051 is derived from a low molecular weight hydroxamic acid scaffold that possessed promising potency (HDAC8; Ki=2 μM) and selectivity (approximately fivefold) for HDAC8 relative to the other class I HDACs. PCI-34051 is found to induce apoptosis at low micromolar concentrations in cell lines derived from T-cell lymphomas, including Jurkat and HuT78, whereas doses as high as 20 μM has no effect on B-cell- or myeloid-derived lymphomas or solid tumor lines[1]. | ||||||||||||
| Name | PCI-34051 | ||||||||||||
| CAS | 950762-95-5 | ||||||||||||
| Formula | C17H16N2O3 | ||||||||||||
| Molar Mass | 296.32 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
PCI-34051
CAS: 950762-95-5 F: C17H16N2O3 W: 296.32
PCI-34051 is a potent and selective HDAC8 inhibitor with IC50 of 10 nM, with >200-fold selectivity over the other HDAC i
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.